HemOnc Today New York

Healio.com brings you the highlights from HemOnc Today New York. Refer back to this page often to read the latest news, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.
Meeting News

Hedgehog inhibitors ‘game changers’ for advanced basal cell carcinoma

March 25, 2017
NEW YORK — Hedgehog inhibitors have demonstrated high efficacy and durability for patients with advanced basal cell carcinoma, according to a…
Meeting News

Baseline factors predict survival benefit from BRAF/MEK inhibitor combination

March 25, 2017
Baseline lactic acid dehydrogenase levels, the sum of target lesion diameters and the number of organ sites with metastases predicted survival…
Meeting News

Molecular testing requires additional validation before ready for prime time in melanoma

March 25, 2017
NEW YORK — Preliminary and validation studies have been conducted on molecular testing methods for melanoma prognostication, but these methods…
Meeting NewsVideo

VIDEO: Decision to undergo lymph node dissection remains ‘complicated’

March 25, 2017
NEW YORK — Vernon K. Sondak, MD, chair of the department of cutaneous oncology at Moffitt Cancer Center and a HemOnc Today Editorial Board…
Meeting News

‘Major need’ exists for more effective mucosal melanoma treatments

March 25, 2017
NEW YORK — Although immunotherapy and targeted agents have demonstrated some promise for mucosal melanoma, outcomes in this patient population…
Meeting News

Gene mutation burden linked to primary site of melanoma

March 25, 2017
NEW YORK — Overall mutation burden appeared to be associated with the primary site of malignant melanoma, according to retrospective study…
Meeting News

Dabrafenib plus trametinib demonstrates long-term tolerability in BRAF V600–mutated melanoma

March 24, 2017
NEW YORK — Extended treatment with dabrafenib plus trametinib demonstrated consistent tolerability profiles in patients with BRAF
Meeting News

Strategies to detect immune-based biomarkers evolving for melanoma treatment

March 24, 2017
NEW YORK — Several blood- and tissue-based assays are in development to identify appropriate treatment options for patients with melanoma…
Meeting News

Choosing adjuvant melanoma therapy remains ‘controversial, tough’

March 24, 2017
NEW YORK — Interferon and ipilimumab are options for the adjuvant treatment of many patients with melanoma, but data are lacking comparing…
Meeting NewsVideo

VIDEO: Artificial intelligence may be feasible for melanoma diagnosis

March 24, 2017
NEW YORK — Smartphone applications and other forms of artificial intelligence have the potential to be valuable tools for the detection of…